Title: Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies.
Journal: Journal of Crohn's & colitis20180101
Title: Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials.
Journal: Gut20170601
Title: Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
Journal: The New England journal of medicine20170504
Title: Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction.
Journal: Arthritis & rheumatology (Hoboken, N.J.)20170101
Title: Effects of the Janus Kinase Inhibitor, Tofacitinib, on Testicular Leydig Cell Hyperplasia and Adenoma in Rats, and on Prolactin Signaling in Cultured Primary Rat Leydig Cells.
Journal: Toxicological sciences : an official journal of the Society of Toxicology20170101
Title: Tofacitinib and analogs as inhibitors of the histone kinase PRK1 (PKN1).
Journal: Future medicinal chemistry20160901
Title: Tofacitinib for the treatment of psoriasis.
Journal: Expert opinion on pharmacotherapy20160701
Title: Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis.
Journal: Rheumatology (Oxford, England)20160601
Title: Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study.
Journal: Journal of the American Academy of Dermatology20160501
Title: Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study.
Journal: The Journal of allergy and clinical immunology20160401
Title: Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma.
Journal: Blood20160310
Title: Elucidating the Mechanism of Tofacitinib Oxidative Decyanation.
Journal: Drug metabolism letters20160101
Title: Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials.
Journal: Clinical and experimental rheumatology20160101
Title: Differences in gene expression and alterations in cell cycle of acute myeloid leukemia cell lines after treatment with JAK inhibitors.
Journal: European journal of pharmacology20151015
Title: Janus Kinase Inhibitor Tofacitinib Shows Potent Efficacy in a Mouse Model of Autoimmune Lymphoproliferative Syndrome (ALPS).
Journal: Journal of clinical immunology20151001
Title: Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.
Journal: Oncotarget20150821
Title: Effects of tofacitinib on nucleic acid metabolism in human articular chondrocytes.
Journal: Modern rheumatology20150701
Title: The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.
Journal: Annals of the rheumatic diseases20150601
Title: Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.
Journal: Leukemia20150401
Title: White-to-brown metabolic conversion of human adipocytes by JAK inhibition.
Journal: Nature cell biology20150101
Title: Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs.
Journal: Arthritis research & therapy20150101
Title: Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis.
Journal: The Journal of investigative dermatology20141201
Title: Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases.
Journal: Journal of medicinal chemistry20140626
Title: Reversal of CD8 T-cell-mediated mucocutaneous graft-versus-host-like disease by the JAK inhibitor tofacitinib.
Journal: The Journal of investigative dermatology20140401
Title: Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro.
Journal: Antimicrobial agents and chemotherapy20140401
Title: JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma.
Journal: Leukemia20140201
Title: Effects of topical Janus kinase inhibition on ocular surface inflammation and immunity.
Journal: Cornea20140201
Title: IL-6-mediated induction of matrix metalloproteinase-9 is modulated by JAK-dependent IL-10 expression in macrophages.
Journal: Journal of immunology (Baltimore, Md. : 1950)20140101
Title: JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis.
Journal: Journal of immunology research20140101
Title: Comparative pathophysiology, toxicology, and human cancer risk assessment of pharmaceutical-induced hibernoma.
Journal: Toxicology and applied pharmacology20131215
Title: Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds.
Journal: Clinical and experimental immunology20131201
Title: Tofacitinib, a janus kinase inhibitor demonstrates efficacy in an IL-15 transgenic mouse model that recapitulates pathologic manifestations of celiac disease.
Journal: Journal of clinical immunology20130401
Title: Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors.
Journal: Arthritis and rheumatism20121201
Title: JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production.
Journal: Arthritis and rheumatism20121101
Title: Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year.
Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons20120901
Title: Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.
Journal: The British journal of dermatology20120901
Title: Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
Journal: The New England journal of medicine20120816
Title: Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.
Journal: The New England journal of medicine20120809
Title: Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.
Journal: The New England journal of medicine20120809
Title: [Janus kinase inhibitors].
Journal: Zeitschrift fur Rheumatologie20120801
Title: Tofacitinib for the treatment of moderate to severe rheumatoid arthritis.
Journal: Drugs of today (Barcelona, Spain : 1998)20120801
Title: Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data.
Journal: British journal of clinical pharmacology20120701
Title: Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma.
Journal: Cancer discovery20120701
Title: Profiling of dihydroorotate dehydrogenase, p38 and JAK inhibitors in the rat adjuvant-induced arthritis model: a translational study.
Journal: British journal of pharmacology20120601
Title: Novel small-molecular therapeutics for rheumatoid arthritis.
Journal: Current opinion in rheumatology20120501
Title: A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.
Journal: Arthritis and rheumatism20120401
Title: In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis.
Journal: Annals of the rheumatic diseases20120401
Title: The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon.
Journal: Annals of the rheumatic diseases20120301
Title: EGCG enhances the therapeutic potential of gemcitabine and CP690550 by inhibiting STAT3 signaling pathway in human pancreatic cancer.
Journal: PloS one20120101
Title: Targeting JAK3 in kidney transplantation: current status and future options.
Journal: Current opinion in organ transplantation20111201
Title: Influence of Janus kinase inhibition on interleukin 6-mediated induction of acute-phase serum amyloid A in rheumatoid synovium.
Journal: The Journal of rheumatology20111101
Title: IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis.
Journal: International immunology20111101
Title: A supratherapeutic dose of the Janus kinase inhibitor tasocitinib (CP-690,550) does not prolong QTc interval in healthy participants.
Journal: Journal of clinical pharmacology20110901
Title: Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate.
Journal: Arthritis care & research20110801
Title: Current landscape for T-cell targeting in autoimmunity and transplantation.
Journal: Immunotherapy20110701
Title: Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).
Journal: Journal of immunology (Baltimore, Md. : 1950)20110401
Title: Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family.
Journal: Journal of medicinal chemistry20110113
Title: CP690,550 inhibits oncostatin M-induced JAK/STAT signaling pathway in rheumatoid synoviocytes.
Journal: Arthritis research & therapy20110101
Title: Inhibitory effects of the JAK inhibitor CP690,550 on human CD4(+) T lymphocyte cytokine production.
Journal: BMC immunology20110101
Title: Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection.
Journal: Journal of medicinal chemistry20101223
Title: Population pharmacokinetic analysis of mycophenolic acid coadministered with either tasocitinib (CP-690,550) or tacrolimus in adult renal allograft recipients.
Journal: Therapeutic drug monitoring20101201
Title: Potential of emerging immunosuppressive strategies to improve the posttransplant cardiovascular risk profile.
Journal: Kidney international. Supplement20100901
Title: Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes.
Journal: Best practice & research. Clinical rheumatology20100801
Title: Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6.
Journal: Journal of molecular biology20100716
Title: Novel immunosuppressive agents in kidney transplantation.
Journal: Clinical nephrology20100501
Title: A receptor-independent, cell-based JAK activation assay for screening for JAK3-specific inhibitors.
Journal: Journal of immunological methods20100331
Title: Monitoring of the immunomodulatory effect of CP-690,550 by analysis of the JAK/STAT pathway in kidney transplant patients.
Journal: Transplantation20091027
Title: Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients.
Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons20090801
Title: The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo.
Journal: Arthritis and rheumatism20090701
Title: Effect of CP-690,550, an orally active janus kinase inhibitor, on renal function in healthy adult volunteers.
Journal: Journal of clinical pharmacology20090401
Title: The effect of the JAK inhibitor CP-690,550 on peripheral immune parameters in stable kidney allograft patients.
Journal: Transplantation20090115
Title: Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550).
Journal: Journal of medicinal chemistry20081225
Title: Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics.
Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons20080801
Title: The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.
Journal: Cancer science20080601
Title: The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia.
Journal: European journal of pharmacology20080317
Title: Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis.
Journal: Arthritis research & therapy20080101
Title: Arthritis clinical trial results revealed.
Journal: JAMA20070103
Title: Combined use of the JAK3 inhibitor CP-690,550 with mycophenolate mofetil to prevent kidney allograft rejection in nonhuman primates.
Journal: Transplantation20051227
Title: Effects of JAK3 inhibition with CP-690,550 on immune cell populations and their functions in nonhuman primate recipients of kidney allografts.
Journal: Transplantation20051115
Title: JAK protein kinase inhibitors.
Journal: Drug news & perspectives20050601
Title: Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates.
Journal: Transplantation20050415
Title: The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing.
Journal: Journal of leukocyte biology20041201
Title: JAK3 inhibition, a viable new modality of immunosuppression for solid organ transplants.
Journal: Trends in molecular medicine20041101
Title: Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor.
Journal: Science (New York, N.Y.)20031031
Title: Jiang JK, et al. Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo,3-dpyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550). J Med Chem. 2008 Dec 25;51(24):8012-8.
Title: Onda M, et al. Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts. J Immunol. 2014 Jul 1;193(1):48-55.
Title: LaBranche TP, et al. JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production. Arthritis Rheum. 2012 Nov;64(11):3531-42.
Title: Yagi K, et al. Pharmacological inhibition of JAK3 enhances the antitumor activity of STI571 in human chronic myeloid leukemia. Eur J Pharmacol. 2018 Apr 15;825:28-33.
